Literature DB >> 7553635

Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and nonneoplastic lesions of the human thyroid.

G Ermak1, G Gerasimov, K Troshina, T Jennings, L Robinson, J S Ross, J Figge.   

Abstract

CD44 is a polymorphic family of immunologically related cell surface proteoglycans and glycoproteins implicated in cell-cell and cell-matrix adhesion interactions, lymphocyte activation and homing, cell migration, and tumor metastasis. CD44 exists as a standard form and as multiple isoforms, each generated by alternative splicing of up to 10 variant exons (termed v1-v10) encoding parts of the extracellular domain. Using semiquantitative reverse transcriptase-PCR and Southern hybridization, alternative CD44 mRNA splicing was examined in 10 papillary thyroid carcinomas, 8 nodular goiters, 9 adenomas, 2 cases of thyroiditis, and 3 histologically normal thyroid controls. The amount of input cDNA for the CD44 PCRs was standardized against an internal control gene (glyceraldehyde phosphate dehydrogenase). Four papillary carcinomas showed significant overexpression of CD44 transcripts migrating between 750 and 1000 bp. These cases demonstrated reduced levels of the 482-bp standard isoform transcript. In six papillary cancers, we found a prominent v6-containing isoform at 750 bp that was present in only trace amounts in normal thyroid tissue. It is of interest that similar findings were seen in the majority of the goiters and adenomas but not in the cases of thyroiditis. These results show that deregulation of alternative CD44 splicing is a common feature of disordered thyroid follicular cell growth, both in neoplastic and nonneoplastic lesions. The data imply an important role for CD44, including CD44v6, in the pathogenesis of various thyroid lesions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553635

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  The implications of alternative splicing in the ENCODE protein complement.

Authors:  Michael L Tress; Pier Luigi Martelli; Adam Frankish; Gabrielle A Reeves; Jan Jaap Wesselink; Corin Yeats; Páll Isólfur Olason; Mario Albrecht; Hedi Hegyi; Alejandro Giorgetti; Domenico Raimondo; Julien Lagarde; Roman A Laskowski; Gonzalo López; Michael I Sadowski; James D Watson; Piero Fariselli; Ivan Rossi; Alinda Nagy; Wang Kai; Zenia Størling; Massimiliano Orsini; Yassen Assenov; Hagen Blankenburg; Carola Huthmacher; Fidel Ramírez; Andreas Schlicker; France Denoeud; Phil Jones; Samuel Kerrien; Sandra Orchard; Stylianos E Antonarakis; Alexandre Reymond; Ewan Birney; Søren Brunak; Rita Casadio; Roderic Guigo; Jennifer Harrow; Henning Hermjakob; David T Jones; Thomas Lengauer; Christine A Orengo; László Patthy; Janet M Thornton; Anna Tramontano; Alfonso Valencia
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

2.  Involvement of osteopontin as a core protein in craniopharyngioma calcification formation.

Authors:  SongTao Qi; GuangLong Huang; Jun Pan; Jia Li; Xi'An Zhang; LuXiong Fang; BaoGuo Liu; Wei Meng; YongMing Zhang; XiaoJun Liu
Journal:  J Neurooncol       Date:  2009-11-10       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.